Figure 1. A schematic view of the procedure that contained patient cohorts and technologies used to identify novel biomarkers in peripheral blood of STEMI.

The blood transcriptome scans of ACS patient and normal healthy subjects were performed on two independent experimental sets. To identify the potent molecular signature of STEMI, combined analysis between two data sets was conducted. Then, blood protein levels of putative biomarkers in 40 STEMI and 32 normal samples were measured by ELISA.